Magnolia bags a $20M CPRIT grant to back trial work on new drug; Evotec lines up a new partner on rare genetic diseases
→ Just days after lining up its Series A launch round of $31 million, Magnolia Neurosciences says that its wholly owned subsidiary won a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
